1511 completed, 189 terminated, 141 unknown, 78 recruiting. 2089 Phase 2, 329 Phase 1, 160 Phase 3.
Follow Communicable Diseases: new trials by email Literature Review of Communicable Diseases trials Research Report on Communicable Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Curcumin for HPV Related Cervical Disease Curcumin C3 Complex, Placebo - Neoplasm Cervix | Phase 2 | Not yet recruiting | Lisa Flowers | 200 | 2027-04-01 | 2026-05-08 |
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs ATRN-119, Stereotactic Body Radiation Therapy (SBRT) - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 35 | 2027-01-31 | 2026-10-27 |
| Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa VPM1002 Vaccine, BCG Vaccine, Placebo - Tuberculosis, HIV Infections | Phase 1 / Phase 2 | Withdrawn | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 2026-12-31 | 2026-08-17 | |
| DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg DOR/ISL - HIV-1, HIV Infection | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 45 | 2026-12-23 | 2026-10-07 |
| Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy - Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml - HIV - Human Immunodeficiency Virus | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 36 | 2026-12-01 | 2026-10-01 |
| A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients Entecavell ODT - Hepatitis B Virus, Liver Transplant | Phase 2 | Not yet recruiting | Jongman Kim | 82 | 2026-12-01 | 2026-10-28 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | Phase 2 | Recruiting | Nicky Mehtani, MD, MPH | 30 | 2026-12-01 | 2026-11-09 |
| Baricitinib Curative Repression of HIV-1 Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg - HIV Infection, HIV | Phase 2 | Not yet recruiting | Emory University | 35 | 2026-12-01 | 2026-11-13 |
| A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size Ixazomib 4 mg, Placebo - HIV (Human Immunodeficiency Virus) | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 45 | 2026-11-23 | 2026-11-12 |
| Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) PRGN-2012, Bevacizumab - Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV) | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 50 | 2026-11-18 | 2026-11-13 |
| Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine 10vHPV, Gardasil9 - Human Papillomavirus Infection | Phase 1 / Phase 2 | Not yet recruiting | Serum Institute of India Pvt. Ltd. | 72 | 2026-11-01 | 2026-11-06 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, Placebo, TVAX-008 - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Ausper Biopharma Co., Ltd. | 105 | 2026-10-31 | 2026-10-19 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) Isoniazid, Rifampin, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 | 2026-08-19 |
| A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB) HT-101 + HT-102, HT-101 placebo + HT-102 placebo - Chronic Hepatitis B Virus Infection | Phase 2 | Not yet recruiting | Suzhou HepaThera Biotech Co., Ltd. | 120 | 2026-10-30 | 2026-11-05 |
| Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues YKYY013, YKYY013 Placebo - HBV (Hepatitis B Virus) | Phase 2 | Not yet recruiting | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 120 | 2026-10-30 | 2026-11-12 |
| A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY) VH4011499, CAB, DTG/3TC - HIV Infections | Phase 2 | Not yet recruiting | ViiV Healthcare | 200 | 2026-10-19 | 2026-09-11 |
| A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer | Phase 2 | Recruiting | University of Maryland, Baltimore | 132 | 2026-10-19 | 2026-11-06 |
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
Showing 20 of 2089. Sign in to see all of them.
HIV Infections (919) · Acquired Immunodeficiency Syndrome (418) · Hepatitis C (339) · Hepatitis C, Chronic (227) · Hepatitis B, Chronic (188) · Hepatitis B (163) · Papillomavirus Infections (91) · AIDS-Related Complex (56) · Infections (51) · Sexually Transmitted Diseases (47) · Hepatitis (46) · Tuberculosis (33) · Virus Diseases (32) · Liver Diseases (27)
Infections (2038) · Virus Diseases (1988) · Blood-Borne Infections (1881) · RNA Virus Infections (1630) · Urogenital Diseases (1304) · Genital Diseases (1298) · Sexually Transmitted Diseases, Viral (1258) · Sexually Transmitted Diseases (1250) · Immune System Diseases (1163) · Lentivirus Infections (1145) · Retroviridae Infections (1145) · Immunologic Deficiency Syndromes (1142) · Digestive System Diseases (797) · Hepatitis, Viral, Human (771)
Ribavirin (229) · peginterferon alfa-2a (133) · Ritonavir (106) · Tenofovir (94) · Zidovudine (80) · Lamivudine (72) · Sofosbuvir (53) · entecavir (53) · Didanosine (49) · efavirenz (46) · Stavudine (45) · Emtricitabine (44) · peginterferon alfa-2b (37) · Lopinavir (35) · Indinavir (32)
National Institute of Allergy and Infectious Diseases (NIAID) (297) · Gilead Sciences (90) · Merck Sharp & Dohme LLC (73) · GlaxoSmithKline (61) · Bristol-Myers Squibb (43) · ViiV Healthcare (41) · Hoffmann-La Roche (32) · French National Agency for Research on AIDS and Viral Hepatitis (30) · National Cancer Institute (NCI) (30) · ANRS, Emerging Infectious Diseases (29) · Boehringer Ingelheim (24) · Centers for Disease Control and Prevention (21) · Tibotec Pharmaceuticals, Ireland (19) · National Center for Complementary and Integrative Health (NCCIH) (17) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (17)
United States (1077) · France (185) · Puerto Rico (180) · Canada (173) · Germany (152) · China (140) · Spain (131) · United Kingdom (125) · South Africa (123) · Italy (91) · Thailand (91) · Australia (88) · Belgium (71) · New Zealand (67) · South Korea (65)
Kiat Ruxrungtham, MD (7) · Marc G Ghany, M.D. (7)
PMID 40190112, PMID 41276263, PMID 34895272, PMID 25424918, PMID 28193518, PMID 30012435, PMID 30923816, PMID 30977945, PMID 34817414, PMID 40342086, PMID 40655875, PMID 18832244, PMID 18832245, PMID 19118378, PMID 19191652, PMID 20091678, PMID 20657177, PMID 20672447, PMID 20703158, PMID 22336878, PMID 24154738, PMID 24209977, PMID 24391139, PMID 24419064, PMID 24983020, PMID 25164700, PMID 25296098, PMID 25445400, PMID 25820067, PMID 25830171, PMID 26596948, PMID 26683763, PMID 26691547, PMID 26752189, PMID 26902761, PMID 27257978, PMID 27566633, PMID 28340322, PMID 28412293, PMID 28802814, PMID 28802816, PMID 30850240, PMID 31042791, PMID 31108015, PMID 31179503, PMID 31464859, PMID 31568620, PMID 31824943, PMID 32827835, PMID 33493795
2014 (22), 2009 (16), 2015 (16), 2016 (14), 2008 (12), 2019 (11), 2023 (8), 2004 (7), U01CA121947 (6), UM1CA121947 (6), 2017 (5), 2018 (5), U01AI068636 (5), 2005 (4), 2025 (4)